Iris J M Levink
Overview
Explore the profile of Iris J M Levink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levink I, Balduzzi A, Kunovsky L, Neesse A
United European Gastroenterol J
. 2024 Dec;
13(1):5-6.
PMID: 39665541
No abstract available.
2.
Hamesch K, Cahyadi O, Dimitriadis S, Hollenbach M, Acedo P, Ayari M, et al.
United European Gastroenterol J
. 2024 Nov;
PMID: 39601382
Background: Endoscopic retrograde cholangiopancreatography (ERCP) still has a relatively high complication rate, underscoring the importance of high-quality training. Despite existing guidelines, real-world data on training conditions remain limited. This pan-European...
3.
Meziani J, de Jong J, Fuhler G, Koopmann B, Levink I, Fockens P, et al.
Clin Transl Gastroenterol
. 2024 Oct;
15(12):e00777.
PMID: 39413349
Introduction: Several studies suggest that new-onset diabetes mellitus is an early manifestation of pancreatic ductal adenocarcinoma (PDAC). Therefore, the International Cancer of the Pancreas Screening Consortium recommends glucose and hemoglobin...
4.
Levink I, Balduzzi A, Marafini I, Kani H, Maeda Y
United European Gastroenterol J
. 2024 Jun;
12(6):664-666.
PMID: 38837304
No abstract available.
5.
Levink I, Jansen M, Azmani Z, van IJcken W, van Marion R, Peppelenbosch M, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685923
Molecular profiling may enable earlier detection of pancreatic cancer (PC) in high-risk individuals undergoing surveillance and allow for personalization of treatment. We hypothesized that the detection rate of DNA mutations...
6.
Levink I, Balduzzi A, Drenth J
United European Gastroenterol J
. 2023 Jul;
11(7):596-598.
PMID: 37515499
No abstract available.
7.
Levink I, Jaarsma S, Koopmann B, van Riet P, Overbeek K, Meziani J, et al.
United European Gastroenterol J
. 2023 Jul;
11(7):601-611.
PMID: 37435855
Background: Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate...
8.
Overbeek K, Koopmann B, Levink I, Tacelli M, Erler N, Arcidiacono P, et al.
Clin Gastroenterol Hepatol
. 2023 Apr;
22(1):62-71.e7.
PMID: 37031711
Background And Aims: In high-risk individuals (HRIs), we aimed to assess the cumulative incidence of intraductal papillary mucinous neoplasms (IPMNs) and compare IPMN growth, neoplastic progression rate, and the value...
9.
Levink I, Srebniak M, De Valk W, van Veghel-Plandsoen M, Wagner A, Cahen D, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982172
Secretin-stimulated pancreatic juice (PJ), collected from the duodenum, presents a valuable biomarker source for the (earlier) detection of pancreatic cancer (PC). Here, we evaluate the feasibility and performance of shallow...
10.
Balduzzi A, Campani C, Dugic A, Elshaarawy O, Levink I, Pisani A, et al.
United European Gastroenterol J
. 2023 Jan;
11(1):131-133.
PMID: 36654489
No abstract available.